Suggested remit - To evaluate the benefits and costs of ravulizumab within its marketing authorisation for treating atypical haemolytic uraemic syndrome for national commissioning by NHS England.
Status Proposed
Process STA 2018
ID number 1530

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
27 January 2020 (10:00) Scoping workshop (London)
02 December 2019 - 09 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance